Inflammatory mediators in various molecular pathways involved in the development of pulmonary fibrosis
- 1 July 2021
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 96, 107608
Abstract
No abstract availableKeywords
Funding Information
- Department of Biotechnology
This publication has 99 references indexed in Scilit:
- Cytokine-Like Factor 1 Gene Expression Is Enriched in Idiopathic Pulmonary Fibrosis and Drives the Accumulation of CD4+ T Cells in Murine LungsThe American Journal of Pathology, 2012
- Statins and Pulmonary Fibrosis: The Potential Role of NLRP3 Inflammasome ActivationAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Inflammation-Induced Endothelial-to-Mesenchymal TransitionThe American Journal of Pathology, 2011
- Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung diseaseArthritis & Rheumatism, 2011
- IL-37 is a fundamental inhibitor of innate immunityNature Immunology, 2010
- Macrophage-derived IL-1β stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3Oncogene, 2009
- Pirfenidone Inhibits T-Cell Activation, Proliferation, Cytokine and Chemokine Production, and Host AlloresponsesTransplantation, 2009
- PAI-1 inhibits neutrophil efferocytosisProceedings of the National Academy of Sciences, 2008
- Regulation of Urokinase Receptor Expression by p53: Novel Role in Stabilization of uPAR mRNAMolecular and Cellular Biology, 2007
- Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrixProceedings of the National Academy of Sciences, 2006